Sota J, et al. - Researchers described anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. According to the occurrence of safety concerns, the overall drug retention rate was significantly different; distinguishing between ANA and CAN, significance was maintained only for ANA. The only variable related to the onset of adverse events (AE) was the treatment duration. An excellent safety profile was demonstrated by ANA and CAN. Findings suggested a decrease in the risk for AE and serious AE (sAE) over time from the start of IL-1 inhibition.